Kane BiotechKNBIF +5.19% Gross Margin % is -9.68% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 738 Biotechnology companies, Kane Biotech ranks worse than 95.8% on this metric.
The historical rank and industry rank for Kane Biotech's Gross Margin % or its related term are showing as below:
KNBIF'
s Gross Margin % Range Over the Past 10 Years
Min: -81.03 Med: 37.64 Max: 73.15
Current: -81.03
During the past 13 years, the highestGross Margin % of Kane Biotech was 73.15%. The lowest was -81.03%. And the median was 37.64%.
KNBIF's Gross Margin % is ranked worse than 95.8% of 738
companies
in the Biotechnology industry
Industry Median: 60.94
vs KNBIF: -81.03
Kane Biotech had a gross margin of -9.68% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Kane Biotech was 0.00% per year.
Kane Biotech (OTCPK:KNBIF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Kane Biotech had a gross margin of -9.68% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Kane Biotech Gross Margin % Related Terms
Kane Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Kane Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNBIF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Kane Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Kane Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Kane Biotech (KNBIF) has a Gross Margin % of -9.68% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Kane Biotech and its competitors. According to the industry distribution chart, Kane Biotech ranks #707 out of 738 companies in the Biotechnology industry, placing it in the top 95.8%.
Is Kane Biotech's Gross Margin % too high?
Kane Biotech's current Gross Margin % is -9.68%. Based on the distribution chart, Kane Biotech ranks #707 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Kane Biotech's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #707 out of 738 companies for Gross Margin %. This places Kane Biotech in the lower half of its industry. The industry median Gross Margin % is 60.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Kane Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current Gross Margin % is -9.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Gross Margin % of -9.68%. The current Gross Margin % is -9.68%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Gross Margin % is -9.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 